Susan Berson and Brent Henry Recognized as Health Care Trailblazers by the National Law Journal
Filter by:
Structuring Your Company for Cross-Border Opportunities in Life Sciences
November 14, 2024
An article written by International Life Sciences Chair Cheryl Reicin and Associate Luke Jeagal was published in BIOTECanada's Insights Magazine focusing on how life sciences companies should structure themselves so that they have cross-border opportunities.
Insurance Industry Key in Net-Zero Transition, UN Group Says
November 14, 2024
ESG Co-chair Jacob Hupart was quoted by Law360 Insurance Authority in an article focused on how the insurance industry is crucial in the transition process to a net-zero economy, according to a recent report by the United Nations' insurance-climate initiative.
Mintz Recovers Over $400M for Institutional Investor Clients in 2024
November 14, 2024
Mintz's Institutional Investor Class Action Recovery Practice has recovered $400 million for institutional investor clients in 2024 and expects projects for recoveries exceeding $500 million by year end.
Trump EPA Pick Seen Supporting PFAS Limits, Revising Water Rules
November 13, 2024
Environmental Practice Chair Jeffrey Porter was quoted by Bloomberg Law in an article about Trump's selection of Rep. Lee Zeldin as EPA administrator and how the pick is expected to support PFAS restrictions and roll back regulations governing wetlands.
Mintz Serves as Expert Contributor to University of Oxford Report on Climate Regulations
November 13, 2024
Mintz is one of two US law firms invited by Oxford University to serve as an expert pro bono contributor to its Climate Policy Monitor, an annual report on global climate regulations which launched today. Including a granular survey of 30 major countries’ net zero implementation (G20+), the research gives the most detailed view yet of how economic rules align—or not—to climate goals.
Member Richard Gervase was quoted by IAM in an article about an increase in the sale of drug royalties over the past two months, including the monetization of a patent deal relating to the world's first approved CRISPR-Cas9 therapy, Casgevy.